ADAPTIVE BIOTECHNOLOGIES

Robert Hershberg’s recent $6.32 buy‑back of 15,000 Adaptive Biotechnologies shares signals insider confidence and a potential upside, but investors should weigh the company’s earnings outlook and market volatility.

CEO Chad M. Robins’ deep‑price buys and hefty block sales at Adaptive Biotechnologies signal insider confidence yet hint at short‑term volatility risks.

Adaptive Biotech insider selling: CFO Susan Bobulsky sold 1,299 shares in July 2026. Understand the impact on stock, sentiment, and long‑term outlook.

Adaptive Biotechnologies insider buying shows cautious optimism: Benzeno’s 10b5‑1 trades signal confidence in the company’s growth and valuation.

Rule 10b‑5‑1 plan sales by Adaptive’s chief scientist show a routine, strategic sell‑off, not a market panic—insider confidence remains strong.